

aThis Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/032217 A3

- (51) International Patent Classification?: A61K 9/50, 9/20 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US00/30082
- (22) International Filing Date: 30 October 2000 (30.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/432,881 2 November 1999 (02.11.1999) US
- (71) Applicant: DEPOMED, INC. [US/US]; 1360 O'Brien Drive, Menlo Park, CA 94025 (US).
- (72) Inventors: MARKEY, Micheline; 2-3727 E. Cliff Drive No 5, Santa Cruz, CA 95062 (US). SHELL, John, W.; 952 Tournament Drive, Hillsborough, CA 94010 (US). BERNER, Bret; 239 El Granada Boulevard, El Granada, CA 94018 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
18 July 2002
- (74) Agents: HEINES, M., Henry et al.; Townsend and Townsend and Crew LLP, 8th Floor, Two Embarcadero Center, San Francisco, CA 94111 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/032217 A3

(54) Title: PHARMACOLOGICAL INDUCEMENT OF THE FED MODE FOR ENHANCED DRUG ADMINISTRATION TO THE STOMACH

(57) Abstract: Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, B-casomorphins, a-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.

PHARMACOLOGICAL INDUCEMENT OF THE FED MODE FOR ENHANCED DRUG ADMINISTRATION TO THE STOMACH

BACKGROUND OF THE INVENTION

1. Field of the Invention

5 This invention is in the general field of pharmacology, and relates in particular to oral dosage formulations that deliver drugs by controlled release in the stomach for a prolonged period of time.

2. Description of the Prior Art

10 Many drugs have their greatest therapeutic effect when released in the stomach, particularly when the release is prolonged in a continuous, controlled manner. Drugs delivered in this manner cause less side effects and provide their therapeutic effects without the need for repeated dosages, or with a low dosage frequency. Localization of the drug delivery in the stomach is an advantage for the treatment of local disorders of the stomach such as esophageal reflux disease, for the eradication of ulcer-causing bacteria in
15 the gastric mucosa, and for the treatment of disorders that require sustained antacid action. Sustained release in the stomach is also useful for therapeutic agents that the stomach does not readily absorb, since sustained release prolongs the contact time of the agent in the stomach or in the upper part of the small intestine, which is where absorption occurs and contact time is limited. Under normal or average conditions, for example,
20 material passes through the small intestine in as little as 1 to 3 hours. For drugs that are absorbed almost exclusively in the small intestine, such as captopril and the cephalosporins, this short contact time limits the bioavailability of these drugs, particularly when the drugs are administered in a controlled-release dosage form.

 The passage of matter through the stomach can be delayed in the normal
25 digestive process by the physiological condition that is variously referred to as the digestive mode, the postprandial mode, or the "fed mode" (the latter term is used in the remainder of this specification for convenience). When the stomach is not in this mode, it is in the interdigestive or "fasting" mode. The difference between the two modes lies in the pattern of gastroduodenal motor activity.

30 In the fasting mode, the stomach exhibits a cyclic activity called the interdigestive migrating motor complex (IMMC). This activity occurs in four phases:

In Phase I, which lasts 45 to 60 minutes and is the most quiescent, few or no contractions occur.

In Phase II, irregular intermittent sweeping contractions occur that gradually increase in magnitude.

5 In Phase III, intense bursts of peristaltic waves appear in both the stomach and the small bowel. This lasts for 5 to 15 minutes.

Phase IV is a transition period of decreasing activity which lasts until the next cycle begins.

The total cycle time is approximately 90 minutes, and the contents of the
10 stomach are swept out by the powerful peristaltic waves that occur during Phase III. Phase III of the IMMC thus functions as an intestinal housekeeper, sweeping swallowed saliva, gastric secretions, food particles, and particulate debris to the small intestine and colon, and preparing the upper tract for the next meal while preventing bacterial overgrowth. Pancreatic exocrine secretion of pancreatic peptide and motilin also cycle in
15 synchrony with the motor pattern.

The fed mode is induced by nutritive elements immediately after food ingestion, and begins with a rapid and profound change in the motor pattern of the upper gastrointestinal GI tract, the change occurring over a period of 30 seconds to one minute. The change occurs almost simultaneously at all sites of the GI tract, before the stomach
20 contents have reached the distal small intestine. Once the fed mode is established, the stomach generates 3-4 continuous and regular contractions per minute, similar to those of the fasting mode but of about half the amplitude. The pylorus is partially open, causing a sieving effect in which liquids and small particles flow continuously from the stomach into the intestine while indigestible particles greater in size than the pyloric opening are
25 retropelled and retained in the stomach. This sieving effect thus causes the stomach to retain particles exceeding about 1 cm in size for approximately 4 to 6 hours.

The minimum particle size that will be retained in the stomach is thus substantially smaller in the fed mode than in the fasting mode. Particles large enough to be retained in the fasting mode are too large for practical administration in most patients.
30 Particles of a smaller particle size can be retained in the stomach if they are administered to a patient who is in the fed mode, and this serves as an effective and feasible means of prolonging the residence time of these particles in the stomach.

While onset of the fed mode is normally caused by the ingestion of a meal, the use of a meal as a means of prolonging the residence time of a drug in the stomach

has certain disadvantages. One disadvantage is a lack of reliability, since although a variety of nutritive elements are capable of inducing the fed mode, different individuals consume meals of different compositions, some inducing the fed mode more easily and for different durations than others. Another disadvantage is that many drugs are
5 adversely affected by the presence of food in the stomach. Thus, a meal-induced fed mode can increase the absorption of some drugs, while decreasing the absorption of others. These disadvantages are avoided by inducing the fed mode through means other than the ingestion of a meal.

While the fed mode promotes the retention of relatively small particles in
10 the stomach, there are still many patients for whom even these particles are too large to be comfortably ingested. For these patients, particles that are initially small enough for comfortable ingestion and swell to a larger size upon contact with the gastric fluid in the stomach can be used. The swelling can occur as a result of hydration of the particle material upon absorption of water from the gastric fluid. Alternatively, the swelling can
15 occur as a result of gas generation, such as carbon dioxide for example, by contact of gastric fluid with the dosage form, the gas generation occurring in a membrane bag or otherwise within the dosage form. A still further alternative is the use of a large tablet held in a compressed condition by mechanical tension within a small capsule and released to expand to its full relaxed size when the capsule contacts gastric fluid. Whether the
20 particles are large enough for fed mode retention before they are ingested or reach that size by swelling or expansion in the stomach, it is important that the particles retain their size while the drug is released into the gastric fluid. Thus, release of the drug must not itself cause the particle to shrink below the minimum size required for retention in the fed mode. Also, the quantity of drug in the formulation should be controllable independently
25 of the particle size. Thus, while the particles must be large enough to be retained in the stomach and contain enough inert carrier to maintain their size during drug release, there should be no need for the patient to ingest a large number of particles to achieve the needed drug dose.

The need for administering and maintaining particles of appropriate size
30 has been addressed by United States Patent No. 5,007,790 ("Sustained Release Oral Drug Dosage form," Shell, inventor, April 16, 1991). This patent discloses particle-form oral drug delivery systems in which the particles are small when taken orally but swell in the gastric fluid to a diameter of approximately 8 to 11 mm. Swelling to this size requires approximately two hours. Retention of the particles in the stomach while they are

swelling requires that the patient be in the fed mode when the drug is administered, or at least that the swelling occur before the Phase III IMMC waves of the fasting mode begin. With control of the IMMC waves dependent on the timing of the fed mode and the manner in which the fed mode is induced, the particle size and retention are subject to
5 uncertainty, and the duration of the retention is at times, and in some individuals, less than desired.

Induction of the fed mode by pharmacological means is reported in the literature, particularly by J.N. Hunt and his co-workers (*J. Physiol.* 201:327(1968)). The most potent pharmacological agents reported for this purpose are straight-chain fatty
10 acids with optimal activity at a chain length in the vicinity of 12 carbons. Use of these agents for maintaining the fed mode for a period of hours in dogs or humans, however, requires dosages in the range of 0.5 g to 1 g. Other agents that have been reported to induce the fed mode are glucose and tryptophan, but these require even higher dosages. John Stephens and co-workers (*Am. J. Physiol.* (1976) 231:848-853 and *Gastroenterol.*
15 (1975) 69:920-927) reported that amino acids such as glycine, arginine and tryptophan slowed gastric emptying in dogs when administered in excess of 1 g similar to results obtained for glucose. The literature reports that all of these agents, with the exception of tryptophan, slow gastric emptying by their osmolarity and consequently fail to suggest any potent specific agents. The low potency of these reported agents makes it difficult to
20 incorporate them in effective amounts in a sustained-release oral dosage form such as a capsule or tablet since the capsule or tablet must be small enough for ingestion and yet contain effective amounts of the agent, the drug, and any excipients needed for controlling the release of the drug.

R. Groning and G. Heun (*Drug Dev. Ind. Pharm.* 10:527 (1984) and *Int. J. Pharmaceut.* 56:111 (1989)) incorporated salts of myristic acid (the 14-carbon fatty acid)
25 into a double capsule or two-layer immediate release dosage form containing either riboflavin or nitrofurantoin as active drugs. These salts are not of high potency, however, and the amounts administered, 107.5-165 mg per dosage form, had only a marginal effect on gastric retention, increasing the retention time by only about 1 to 2 hours. An agent
30 that can be incorporated into a dosage form at a low dose and yet achieve a mean gastric retention time of 4-6 hours similar to food has not been reported.

SUMMARY OF THE INVENTION

The present invention resides in the discovery of the ability of certain potent substances to cause pharmacological inducement of the fed mode in a patient. These substances, hereinafter referred to as "fed-mode inducing agents," thus serve as a novel means of inducing the fed mode that does not rely on the ingestion of a meal. These agents can be administered separately or combined with a drug in a single dosage form. When combined with a drug, the agents are sufficiently potent that they can be incorporated into sustained-release drug delivery systems of a size practical to swallow. Included among such delivery systems are unit oral dosage forms that contain both the fed-mode inducing agent and the drug supported by a solid matrix that is sufficiently large to promote retention in the stomach during the fed mode or that swells to such a size upon imbibition of water. The fed-mode inducing agents of this invention are as follows.


(a) glycine, glycylglycine, and salts of either of these two compounds

(b) C₄-C₈ sugar alcohols

(c) alkali and alkaline earth metal docusates


(d) β -casomorphins

(e) dithioorganic acids of the formula



in which n is 3 to 13

(f) 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides of the formula



in which:

R¹ is H, lower alkyl, or halo,

R² is H or methyl,

R^3 is $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}(\text{CH}_3)\text{CH}_2-$,


R^4 is lower alkyl, and

R^5 is lower alkyl

(g) arginine and its salts

5 (h) the dipeptide tryptophan-tryptophan ("Trp-Trp") and its salts

(i) alkyl pyridinium halides of the formula



in which n is 8 to 20 and X is halide

(j) dihydroxybenzoic acids

10 and highly potent food sweeteners, such as


(k) stevioside

(l) aspartame and other alkyl esters of N-L- α -aspartyl

L-phenylalanine

(m) aspartic acid and its salts

15 (n) 3,4-dihydro-1,2,3-oxathiazin-4-ones of the formula



in which R^1 and R^2 are the same or different and each is
either a hydrogen atom or an alkyl group having no more
than ten carbon atoms, and salts of these 3,4-dihydro-1,2,3-
20 oxathiazin-4-ones

In certain embodiments of this invention, the fed mode inducing agent is incorporated into a sustained-release drug delivery system that combines the benefits of swellable particles with a pharmacologically induced fed mode to retain the drug delivery system in the stomach of the patient independently of the dietary habits or digestive
25 cycles of the patient. Drug administration is thereby achieved with a high level of control over the site of drug delivery. The invention in these embodiments is a single dosage form for oral administration that includes both a solid-state drug dispersed or otherwise retained in a solid matrix of a water-swelling polymer, and one or more of the fed mode

inducing agents listed above. The water-swella-
ble polymer matrix is in the form of
particles that are small enough for oral administration yet rapidly swell upon imbibition
of water from gastric fluid to a size sufficiently large that they are retained in the stomach
for several hours during the fed mode. The swollen particles maintain their size long
5 enough to be held in the stomach for the desired duration of drug delivery, which is
generally in excess of several hours. The matrix may be susceptible to decomposition by
the action of components in the gastric fluid, or it may tend to dissolve in the gastric fluid,
but in either case at a rate slow enough to maintain the retention-promoting size for the
desired duration. The drug itself is usually soluble or partially soluble in gastric fluid, yet
10 is released from the matrix into the fluid at a limited rate due to the characteristics of the
matrix. The fed mode releasing agent may be incorporated into the dosage form, or
applied as a separate layer or coating over the dosage form, in a manner that will cause
the agent to be released immediately upon contact with the gastric fluid, thereby
imparting its full effect of inducing the fed mode as soon as the dosage form reaches the
15 stomach. Alternatively, the agent may be formulated or incorporated in a manner that
will result in prolonged or sustained release of the agent itself, thereby imparting its fed
mode inducing effect in a continuous and sustained manner.

In other embodiments of this invention, the fed mode inducing agent is
administered in a non-swelling matrix either prior to or concurrently with the drug of
20 interest, the fed mode inducing agent and the drug being in separate dosage forms.
Administered in this manner, the agent can still improve the bioavailability of drugs
formulated for immediate release and of many drugs that are administered as powders.
When administered in a dosage form separate from the drug, the agent can be
incorporated in a tablet or capsule, which can be immediate release or sustained release.
25 When the drug and said agent are incorporated in the same dosage form, the drug and
agent can occupy different layers or regions of a capsule or tablet or the two may be
blended together in the dosage form. The dosage form which is sufficiently large to be
retained in the stomach in the fed mode may be a large non-swelling tablet, a swelling
tablet, an osmotic pump, a hydrogel or other type of dosage form that swells or expands
30 upon contact with gastric fluid, or another sustained-release dosage form.



This invention further resides in pharmaceutical compositions containing a
drug retained in a solid matrix whose size is sufficiently large to promote the retention of
the matrix in the stomach during the fed mode, in combination with a pharmacological
fed mode inducing agent that is retained in a solid matrix, enclosure, or other material or

device that is configured to release the fed mode inducing agent into the stomach in a sustained manner. Fed mode inducing agents contemplated for this aspect of the invention are those whose potency is sufficiently great that onset of the fed mode occurs upon release of as little as 500 mg of the agent or less.

- 5 Details of these and other features and embodiments of the invention are provided below.

DETAILED DESCRIPTION OF THE INVENTION AND SPECIFIC EMBODIMENTS

- 10 One group of fed mode inducing agents of this invention is glycine, glycyglycine and salts thereof. The formulas of prominent members of this group are as follows



- Preferred amounts of this agent in an oral drug unit dosage form are in the range of about 1 mg to about 500 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 5 mg to about 150 mg.

Further fed mode inducing agents of this invention are those of the group defined as sugar alcohols, which are polyols of the general formula




- in which n is a positive integer. Of particular interest are C₄-C₈ sugar alcohols, *i.e.*, those of this formula in which n is 2 to 6. Xylitol, whose formula is



- is a preferred member of this group. Preferred amounts of sugar alcohols in an oral drug unit dosage form are in the range of about 30 mg to about 1000 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 100 mg to about 800 mg.


The alkali and alkaline earth metal docusates of this invention are structures in which the anion has the formula



and the cation is either an alkali metal ion or an alkaline earth metal ion. Calcium and sodium docusates are preferred, and sodium docusate is particularly preferred. Preferred amounts of alkali and alkaline earth metal docusates in an oral drug unit dosage form are in the range of about 30 mg to about 1000 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 50 mg to about 400 mg.


The β -casomorphins of this invention include the naturally occurring peptides released from β -casein by the action of acid and pepsin. These naturally occurring peptides include both bovine and human β -casomorphins. The sequence of bovine β -casomorphin is Tyr-Pro-Phe-Pro-Gly-Pro-Ile, while the sequence of human β -casomorphin is Tyr-Pro-Phe-Val-Glu-Pro-Ile. Also included are fragments and synthetic derivatives and analogs of β -casomorphins that have μ -opioid activity and improved stability in the GI tract to acid and peptidases. These include, but are not limited to, Tyr-Pro-Phe, Tyr-Pro-Phe-amide, Tyr-D-Ala-Phe-amide, Tyr-D-Ala-Phe-D-Pro-Tyr-amide, Tyr-D-Ala-Phe-Pro-Tyr-amide, Tyr-D-Ala-Phe-D-Ala-Tyr-amide, Tyr-Pro-Phe-Pro, Tyr-Pro-Phe-Pro-amide, Tyr-D-Ala-Phe-(pCl)Phe-Pro-amide, Tyr-D-Ala-Phe-Pro-amide, Tyr-Pro-Val-Pro-amide, Tyr-Pro-Phe-Pro-Gly-amide, Tyr-D-Ala-Phe-Pro-Gly-amide, Tyr-D-Pro-Phe-Pro-Gly-amide, Tyr-Pro-Phe-Pro-Gly, Tyr-Pro-Phe-Pro-Gly-Pro, Tyr-Pro-Phe-Pro-amide, Pro-Phe-Pro-Gly-Pro-Ile, Tyr-Pro-(nMe)Phe-D-Pro-amide, and Tyr-Pro-Phe-D-Pro-amide. Preferred amounts of β -casomorphins in an oral drug unit dosage form are in the range of about 1 mg to about 300 mg. In the most preferred embodiments of this invention when an agent of this class is used, the amount ranges from about 5 mg to about 150 mg.

Of the dithioorganic acids of this invention, whose generic formula is shown above, the preferred example is α -lipoic acid, the formula of which is




Preferred amounts of dithioorganic acids in an oral drug unit dosage form are in the range of about 30 mg to about 1000 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 40 mg to about 300 mg.

- 5 The 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides of this invention, whose generic formula is given above, are synthetic opiates. In the definitions associated with this formula, the term "lower alkyl" denotes C₁-C₆ alkyl, preferably C₁-C₃ alkyl, more preferably methyl or ethyl, and "halo" denotes fluoro, chloro, bromo, or iodo, preferably fluoro or chloro, and most preferably chloro. Preferred species are those in which R¹ is halo, more preferably 4-halo, still more preferably 4-fluoro or 4-chloro, and R⁴ and R⁵ are each either methyl or ethyl. A specific example of a species within the generic formula is 4-(*p*-chlorophenyl)-4-hydroxy-*N,N*-dimethyl- α,α -diphenyl-1-piperidinebutyramide, which bears the generic name loperamide and is generally available as a monohydrochloride salt. Loperamide is commercially available from Ortho
10 Pharmaceutical Corporation, Raritan, New Jersey, USA, under the name IMODIUM as a therapeutic agent for controlling diarrhea. The formula for loperamide is



- This compound and other 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides are disclosed in United States Patent No. 3,714,159 (Janssen *et al.*, January 30, 1973), the contents of which are incorporated herein by reference. Preferred amounts of the 2,2-
20 diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides for use in an oral drug unit dosage form in accordance with the present invention are in the range of about 0.5 mg to about 300 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 2 mg to about 15 mg.


- 25 Arginine has the formula



Preferred amounts of arginine in an oral drug unit dosage form are in the range of about 3 mg to about 300 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 30 mg to about 250 mg.

- 5 Salts of glycine and arginine that are suitable for this invention include nontoxic salts, preferably cationic salts and hydrohalide or hemihydrohalide salts. The sodium, potassium, calcium, hemihydrochloride, and hydrochloride salts are the most preferred examples.

The peptide Trp-Trp has the formula




10

Preferred amounts of Trp-Trp in an oral drug unit dosage form are in the range of about 0.05 mg to about 300 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 0.5 mg to about 10 mg.

- 15 Salts of Trp-Trp that are suitable for this invention include nontoxic salts, preferably cationic salts and hydrohalide or hemihydrohalide salts. The sodium, potassium, calcium, hemihydrochloride, and hydrochloride salts are the most preferred examples.


- 20 Of the alkyl pyridinium halides of this invention, whose formula is shown above, the preferred examples are those in which n is 12 to 16 and, separately, those in which X is chloride, or those in which both n is 12 to 16 and X is chloride. A particularly preferred alkyl pyridinium halide is cetyl pyridinium chloride in which n is 14 and X is Cl. Preferred amounts of alkyl pyridinium halides in an oral drug unit dosage form are in the range of about 0.1 mg to about 200 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 0.5 mg to about 50 mg.

Of the dihydroxybenzoic acids of this invention, the preferred example is gentisic acid or its natural source gentian root. The chemical name of gentisic acid is 2,5-dihydroxybenzoic acid, of the formula




- 5 Preferred amounts of dihydroxybenzoic acids in an oral drug unit dosage form are in the range of about 3 mg to about 300 mg. In the most preferred embodiments of this invention when this agent is used, the amount ranges from about 10 mg to about 100 mg.

The sweetener stevioside has the generic name 13-[(2-O-β-D-glucopyranosyl-α-D-glucopyranosyl)oxy]kaur-16-en-18-oic acid β-glucopyranosyl ester, and the formula




The alkyl esters of N-L-α-aspartyl L-phenylalanine have the generic formula:



in which R is lower alkyl, preferably C₁-C₄ alkyl. Aspartame is the methyl ester, *i.e.*, the species in which R is a methyl group.

Aspartic acid has the formula



5 Of the 3,4-dihydro-1,2,3-oxathiazin-4-ones of the invention, whose formula is shown above, a preferred group is those in which R¹ and R² (independently) are either H or C₁-C₄ alkyl, and a more preferred group is those in which R¹ is C₁-C₄ alkyl and R² is H. The most preferred example is that in which R¹ is methyl and R² is H. This compound is known as acesulfame and by the generic name 6-methyl-1,2,3-oxathiazin-
10 4(3H)-one 2,2-dioxide. Suitable salts of 3,4-dihydro-1,2,3-oxathiazin-4-ones for use in this invention are nontoxic salts, particularly cationic edible salts. The potassium, sodium, and calcium salts are preferred, particularly as salts of acesulfame.

 Of the sweeteners of this invention, the most preferred is aspartame. Preferred amounts of these sweeteners in an oral drug dosage form are in the range of
15 about 30 mg to about 800 mg. In the most preferred embodiments of this invention where sweeteners are used, the amount ranges from about 50 mg to about 400 mg.

 Fed mode inducing agents in accordance with this invention can be incorporated in the dosage forms in any of various ways. An agent may, for example, be incorporated in such a manner that the agent is released substantially immediately into the
20 gastric fluid as soon as the dosage form enters the stomach. Alternatively, an agent may be incorporated in such a manner that it is released into the gastric fluid in a sustained manner, such as by dissolution and diffusion out of a solid matrix in which the agent is retained, or by slow erosion of the solid matrix. A still further alternative is a combination whereby a portion of the agent is released immediately and the remainder is
25 released in a sustained manner. In either case, the drug itself is preferably retained in a solid matrix that releases the drug from the matrix in a sustained (*i.e.*, continuous and prolonged) manner.

 Solid matrices that provide sustained release of substances (drugs, fed mode inducing agents, or both) in the practice of this invention may assume any of
30 various forms. One form is a solid mass impregnated with the substance(s) and releasing the substance(s) either by dissolution of the substance(s) into gastric fluid that is gradually imbibed by the matrix mass and diffusion of the dissolved substance(s) out of the mass. Another is a solid mass impregnated with the substance(s), the mass itself

being gradually erodible upon contact with gastric fluid and releasing the substance(s) by the process of erosion. A third is an osmotic dispensing device, which is a compartmented enclosure with one compartment containing the substance(s) to be dispensed and another (or part of the same compartment) that has a permeable wall through which gastric fluid enters by osmosis. When the device contains separate compartments, they are separated by a flexible or movable wall, and the entering gastric fluid forces the substance out of the enclosure through a dispensing port. Dispensing of the substance(s) thus occurs by osmotic pressure. Disclosures of osmotic dispensing devices of this general type are found in United States patents nos. 3,916,899 (inventors Theeuwes, Felix, *et al.*, issue date November 4, 1975), 5,340,590 (inventors Wong, Patrick S.L., *et al.*, issue date August 23, 1994), and 5,938,654 (inventors Wong, Patrick S.L., *et al.*, issue date August 17, 1999). The disclosures of each of these patents are incorporated herein by reference.

For fed mode inducing agents that are released substantially immediately into the gastric fluid, either in whole or in part, such immediate release can be achieved by placing most, and preferably all, of the fed mode enhancing agent outside the matrix that retains the drug. One way of achieving this is by including the agent in a solid layer or solid coating over the matrix. Another way is by adding the agent in powdered form to a capsule that also contains the particles of the drug-containing matrix.

When the fed mode inducing agent is contained in a solid layer or coating, the layer or coating preferably consists of the agent retained in a water-soluble matrix that rapidly disintegrates upon contact with the gastric fluid and thereby releases the agent into the fluid. Typical classes of film-forming matrices are cellulosics, vinyls, glycols, acrylics, and other carbohydrates. Examples of cellulosics are hydroxypropyl-methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, carboxymethylcellulose, ethyl cellulose, and microcrystalline cellulose. Examples of vinyls are polyvinylpyrrolidone, crospovidone, and polyvinyl alcohol. Examples of glycols are polyethylene glycols, polyethylene oxides, sodium starch glycolate, and poloxamers. Examples of acrylates are dimethylaminoethylmethacrylate, methacrylic acid copolymers and ethyl acrylate-methyl methacrylate copolymers. Examples of other carbohydrates are maltodextrins, polydextrose, lactose and zein. Sodium starch glycolate and microcrystalline cellulose are particularly preferred. The proportion of the fed mode inducing agent in the water-soluble matrix can vary widely and is not critical. In most cases, however, best results will be obtained with a weight ratio of agent to total water-

swellable matrix in the dosage form ranging from about 0.5:8 to about 3:5, and preferably from about 1:8 to about 2:8. For highly potent agents, ratios that are considerably lower can be used.

While the preferred amounts of each type of fed mode inducing agent in accordance with this invention are stated above, the amount of the fed mode inducing agent used in general in conjunction with an oral drug dosage form is not critical to this invention. Optimal amounts will vary with the type of agent used. For embodiments of the invention in which the drug matrix is a water-swellable polymer, the appropriate amount of fed mode inducing agent for any particular dosage form will be the amount that will induce and maintain the fed mode long enough for the particles of water-swellable polymer to reach a size that is large enough to be retained in the stomach in the fed mode.

When sustained (*i.e.*, continuous and prolonged) release of the fed mode inducing agent is desired, the agent can be retained in a solid matrix such as that described above for the drug, and therefore released from the matrix by dissolution and diffusion, or by slow erosion of the matrix itself. The agent and the drug may thus both be retained in a common solid matrix, or they may be retained in separate solid matrices, each forming a distinct layer of a single tablet, or separate tablets. Placement of the agent and drug in separate matrices permits the use of different matrices to achieve different release rates or profiles of the drug and the agent.

In those embodiments of the invention in which the matrix (containing either the drug, the fed mode inducing agent, or both) is a water-swellable polymer, the polymer is any polymer that is non-toxic, that swells in a dimensionally unrestricted manner upon imbibition of water, and that provides for sustained release of an incorporated ingredient. Examples of polymers suitable for use in this invention are cellulose polymers and their derivatives (such as for example, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, and microcrystalline cellulose, polysaccharides and their derivatives, polyalkylene oxides, polyethylene glycols, chitosan, poly(vinyl alcohol), polysaccharide gums, maleic anhydride copolymers, poly(vinyl pyrrolidone), starch and starch-based polymers, poly (2-ethyl-2-oxazoline), poly(ethyleneimine), polyurethane hydrogels, and crosslinked polyacrylic acids and their derivatives. Further examples are copolymers of the polymers listed in the preceding sentence, including block copolymers and grafted polymers. Specific examples of copolymers are PLURONIC® and TECTONIC®, which are polyethylene oxide-

polypropylene oxide block copolymers available from BASF Corporation, Chemicals Div., Wyandotte, Michigan, USA.

The terms "cellulose polymer" and "cellulosic polymer" are used herein to denote linear polymers of anhydroglucose. Preferred cellulosic polymers are alkyl-substituted cellulosic polymers that ultimately dissolve in the gastrointestinal (GI) tract in a predictably delayed manner. Preferred alkyl-substituted cellulose derivatives are those substituted with alkyl groups of 1 to 3 carbon atoms each. Examples are methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose. In terms of their viscosities, one class of preferred alkyl-substituted celluloses includes those whose viscosity is within the range of about 100 to about 110,000 centipoise as a 2% aqueous solution at 20°C. Another class includes those whose viscosity is within the range of about 1,000 to about 4,000 centipoise as a 1% aqueous solution at 20°C. Particularly preferred alkyl-substituted celluloses are hydroxyethylcellulose and hydroxypropylmethylcellulose. A presently preferred hydroxyethylcellulose is NATRASOL® 250HX NF (National Formulary), available from Aqualon Company, Wilmington, Delaware, USA.

Polyalkylene oxides of greatest utility in this invention are those having the properties described above for alkyl-substituted cellulose polymers. A particularly preferred polyalkylene oxide is poly(ethylene oxide), which term is used herein to denote a linear polymer of unsubstituted ethylene oxide. For agents having high solubility in water, poly(ethylene oxide) polymers having molecular weights of about 4,000,000 and higher are preferred. More preferred are those with molecular weights within the range of about 4,500,000 to about 10,000,000, and even more preferred are polymers with molecular weights within the range of about 5,000,000 to about 8,000,000. Preferred poly(ethylene oxide)s are those with a weight-average molecular weight within the range of about 1×10^5 to about 1×10^7 , and preferably within the range of about 9×10^5 to about 8×10^6 . Poly(ethylene oxide)s are often characterized by their viscosity in solution. For purposes of this invention, a preferred viscosity range is about 50 to about 2,000,000 centipoise for a 2% aqueous solution at 20°C. Two presently preferred poly(ethylene oxide)s are POLYOX® NF, grade WSR Coagulant, molecular weight 5 million, and grade WSR 303, molecular weight 7 million, both products of Union Carbide Chemicals and Plastics Company Inc. of Danbury, Connecticut, USA. Two other preferred poly(ethylene oxide)s are POLYOX® NF, grade WSR 301, molecular weight 4 million,

and grade WSR N60K, molecular weight 2 million, both products of Union Carbide Chemicals and Plastics Company Inc. of Danbury, Connecticut, USA. For agents of low water solubility, release of the agent from the matrix may be achieved at least in part by erosion of the matrix. Poly(ethylene oxide) matrices can be made more erodible by the inclusion poly(ethylene oxide) of a lower molecular weight (less than 1,000,000). Mixtures of polyethylene oxides of different molecular weights can also be used regardless of the water solubility of the agent.

Polysaccharide gums suitable for use in this invention include both natural and modified (semi-synthetic) polysaccharide gums. Examples are dextran, xanthan gum, gellan gum, welan gum and rhamosan gum. Xanthan gum is preferred.

Crosslinked polyacrylic acids of greatest utility are those whose properties are the same as those described above for alkyl-substituted cellulose and polyalkylene oxide polymers. Preferred crosslinked polyacrylic acids are those with a viscosity ranging from about 4,000 to about 40,000 centipoise for a 1% aqueous solution at 25°C. Three presently preferred examples are CARBOPOL® NF grades 971P, 974P and 934P (BFGoodrich Co., Specialty Polymers and Chemicals Div., Cleveland, Ohio, USA). Further examples are polymers known as WATER LOCK®, which are starch/-acrylates/-acrylamide copolymers available from Grain Processing Corporation, Muscatine, Iowa, USA.

The hydrophilicity and water swellability of these polymers cause the drug-containing matrices to swell in size in the gastric cavity due to ingress of water in order to achieve a size that will be retained in the stomach when introduced during the fed mode. These qualities also cause the matrices to become slippery, which provides resistance to peristalsis and further promotes their retention in the stomach. For highly soluble drugs, the release rate of a drug from the matrix is primarily dependent upon the rate of water imbibition and the rate at which the drug dissolves and diffuses from the swollen polymer, which in turn is related to the solubility and dissolution rate of the drug, the drug particle size and the drug concentration in the matrix. For sparingly soluble drugs, the release rate of a drug from the matrix is primarily dependent upon the rate of water imbibition and the rate at which the polymer dissolves in the gastrointestinal fluid or erodes due to the action of the fluid. Also, because these polymers dissolve very slowly in gastric fluid, the matrix maintains its physical integrity over at least a substantial period of time, in many cases at least 90% and preferably over 100% of the dosing period. The particles will then slowly dissolve or decompose. Complete

dissolution or decomposition may not occur until 24 hours or more after the intended dosing period ceases, although in most cases, complete dissolution or decomposition will occur within 10 to 24 hours after the dosing period. For erodible systems, where the main mechanism of drug release is through dissolution of the polymer, dissolution may occur
5 within 2 to 8 hours.

The drug is preferably dispersed homogeneously in the polymeric matrix, although this is not a requirement of the present invention. The weight ratio of drug to polymer is not critical and may vary. In most cases, however, best results will be obtained with a drug:polymer weight ratio within the range of about 1:9 to about 9:1,
10 preferably about 1:1 to about 9:1, and most preferably about 4:1 to about 9:1. For highly potent drugs, a much lower ratio may be used.

The particles are preferably consolidated into a packed mass for ingestion, even though they will separate into individual particles once ingested. Conventional methods can be used for consolidating the particles in this manner. For example, the
15 particles can be placed in gelatin capsules known in the art as "hard-filled" capsules and "soft-elastic" capsules. The compositions of these capsules and procedures for forming them are known among those skilled in drug formulations. The encapsulating material should be highly soluble in gastric fluid so that the particles are rapidly dispersed in the stomach after the capsule is ingested.

One presently preferred dosage form is a size 0 gelatin capsule containing
20 either two or three pellets of drug-impregnated polymer. For two-pellet capsules, the pellets are cylindrically shaped, 6 mm in diameter and 10.5 mm in length. For three-pellet capsules, the pellets are again cylindrically shaped, 6 mm in diameter and 7 mm in length. For a size 00 gelatin capsule with two pellets, the pellets are cylindrical, 7.5 mm
25 in diameter and 11.75 mm in length. For a size 00 gelatin capsule with three pellets, the pellets are cylindrical, 7.5 mm in diameter and 4.8 mm in length. These are merely examples; the shapes and sizes can be varied considerably.

The drugs that serve as therapeutic agents in the oral drug dosage forms of this invention range from those of low solubility in gastric fluid, to those of intermediate
30 solubility and those of high solubility. The dosage form may be adapted to each case.

With drugs of low or limited solubility, it is preferred that portions of the drug be retained in the matrix in solid form for at least about two hours, and yet the drug must be sufficiently soluble to permit the diffusion required to achieve its therapeutic effect. The solubility should thus be high enough to permit diffusion of the drug from the

particle at a rate fast enough to provide an effective level of therapy yet slow enough to extend the treatment over the desired duration. Low solubility drugs of particular interest are those whose solubility (determined in water at 37°C) lies within the range of about 0.005% to about 10% by weight, and preferably from about 0.1% to about 5% by weight.

5 Included among these drugs are those that are effective in eradicating *Helicobacter pylori* from the submucosal tissue of the gastrointestinal tract, particularly the stomach. The oral dosage form of this invention improves the effectiveness of these drugs in treating stomach and duodenal ulcers as well as gastritis and esophagitis, and in reducing the risk of gastric carcinoma. Drugs and drug combinations suggested for these
10 indications include bismuth salts such as bismuth subsalicylate or bismuth citrate, metronidazole, and amoxycillin, other antibiotics such as clarithromycin, thiamphenicol, tetracycline, neomycin or erythromycin, H-2 antagonists such as cimetidine or ranitidine, proton pump inhibitors such as omeprazole, and combinations of these drugs. Preferred drugs for this indication are clarithromycin plus omeprazole, a bismuth salt plus
15 metronidazole, amoxycillin plus metronidazole, and amoxycillin or a bismuth salt plus omeprazole.

Sustained-release dosage forms in accordance with this invention are also of particular value in the administration of drugs such as peptides and proteins that are labile upon exposure to gastric pH or gastric enzymes. These drugs and others of a
20 similarly large molecular size are most efficiently absorbed in the region extending from the lower stomach through the duodenum to the upper part of the small intestine. The formulations of this invention physically protect the undissolved portion of the drug within the water-swellable matrix until the drug dissolves and is thereby released. This results in continuous delivery of undegraded drug at or near this region of high
25 absorptivity for an extended period of time. Therapeutic agents that otherwise require administration by injection can thus provide effective results when administered orally. Examples of such agents are calcitonin, calcitriol and ceftriaxone sodium. Further examples of therapeutic agents that are not efficiently absorbed from the lower G.I. tract and that will therefore benefit from this invention are captopril, simvastatin, cyclosporins,
30 acyclovir, cephalosporins, interleukins, nitrofurantoin, and the ergot alkaloids.

The delivery of drugs in a continuous and prolonged rather than pulse-wise manner provides improved therapy due to better compliance with less frequent dosing. Continuous and prolonged delivery also offers both a reduction in side effects associated

with the drug and the ability to achieve efficacy with less frequent administration.

Examples of therapies in which this is useful are as follows:

- 5 (1) A reduction in angioedema and agranulocytoses, which are side effects arising from the administration of angiotensin-converting enzyme inhibitors such as enalapril maleate and captopril;
- (2) A reduction of anti-cholinergic (drying) and sedative side effects of antihistamines such as clemastine fumarate;
- (3) Prolonged activity for cholesterol lowering drugs such as lovastatin with less frequent administration and reduced side effects such as liver
10 dysfunction, rhabdomyolysis, rash and headache;
- (4) Prolongation of the effects of antidepressant agents such as fluoxetine, with a reduction of the side effects of insomnia and stomach upset;
- (5) With the use of antiepileptic drugs such as carbamazepine, the benefit of only a single daily administration rather than administration three or four times
15 a day as presently required, and a reduction both of side effects and of response variability;
- (6) With potent analgesics such as meperidine, the benefit of steady, prolonged control of pain with reduced drug toxicity;
- (7) Less frequent administration, and less irritation upon use of blood
20 platelet aggregation inhibitors such as ticlopidine; and
- (8) With drugs whose absorption is normally low and highly variable, such as cyclosporine, an increase in the amount absorbed and a decrease in variability between patients.

Similar benefits are obtained with other types of drugs. Calcium channel
25 blockers, such as verapamil, diltiazem, nifedipine, or nicardipine, for example, can be administered with controlled delivery and gastric retention to extend their effects through the night and thereby alleviate early morning hypertension, the cause of many heart attacks. The frequency of administration can also be reduced to a single daily dose. The invention also enhances the treatment of gastroesophageal reflux disease by providing
30 prolonged, localized effects of agents such as pentagastrin, PG-F2, and metaclopramide that improves the competency of lower esophageal sphincter (LES) muscles.

Other drugs that will benefit from the invention include H-2 antagonists such as cimetidine and ranitidine, or calcium carbonate, for ulcer treatment and prevention; non-steroidal anti-inflammatory agents (NSAIDS) such as indomethacin,

ibuprofen, naproxen and piroxicam; steroids such as prednisone, prednisolone and dexamethasone; other NSAIDS such as diclofenac and ketorolac; acyclovir for the treatment of viral diseases such as herpes; tamoxifen for treatment of cancer; chlorpheniramine maleate for allergic disorders; potassium chloride for potassium
5 supplementation, and peptides or other labile molecules such as protease inhibitors for treatment of AIDS. Still further drugs will be apparent to those skilled in pharmacology.

In aspects of this invention that are directed to highly soluble drugs, the drugs thus addressed are those that are characterized by the United States Pharmacopeia XXII as at least "freely soluble" in water, *i.e.*, drugs whose solubility is greater than one
10 part of the drug in about twenty parts of water. Drugs of particular interest are those whose solubility is greater than one part in about ten parts of water, and drugs of even greater interest are those whose solubility is greater than one part in about three parts of water. The parts referred to in this paragraph and throughout this specification are parts by weight. Examples of drugs of high solubility to which this invention is applicable are
15 metformin hydrochloride, vancomycin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, ticlopidine hydrochloride, amoxicillin, cefuroxime axetil, cefaclor, clindamycin, doxifluridine, tramadol, fluoxetine hydrochloride, ciprofloxacin, gancyclovir, bupropion, lisinopril, and esters of ampicillin. Examples of drugs of low solubility to which this invention is applicable are cefaclor,
20 ciprofloxacin, saquinavir, ritonavir, nelfinavir, clarithromycin, azithromycin, ceftazidime, cyclosporin, digoxin, paclitaxel, iron salts, topiramate, and ketoconazole. Other drugs suitable for use and meeting the solubility criteria described above will be apparent to those skilled in the art. Drugs of particular interest are metformin hydrochloride and sertraline hydrochloride. The drug loadings (weight percent of drug relative to total of
25 drug and polymer) in most of these cases will be about 80% or less.

The invention is also of use with drugs that have been formulated to include additives that impart a small degree of hydrophobic character, to further retard the release rate of the drug into the gastric fluid. One example of such a release rate retardant is glyceryl monostearate. Other examples are fatty acids and salts of fatty acids, one
30 example of which is sodium myristate. The quantities of these additives when present can vary; and in most cases, the weight ratio of additive to drug will range from about 1:20 to about 1:1, and preferably from about 1:8 to about 1:2.

The particulate drug/polymer mixture or drug-impregnated polymer matrix can be prepared by various conventional mixing and comminution techniques readily

apparent to those skilled in the chemistry of drug formulations. Examples of such techniques are as follows:

(1) Direct compression, using appropriate punches and dies, such as those available from Elizabeth Carbide Die Company, Inc., McKeesport, Pennsylvania, USA; the punches and dies are fitted to a suitable rotary tableting press, such as the Elizabeth-Hata single-sided Hata Auto Press machine, with either 15, 18 or 22 stations, and available from Elizabeth-Hata International, Inc., North Huntingdon, Pennsylvania, USA; and

(2) Injection or compression molding using suitable molds fitted to a compression unit, such as those available from Cincinnati Milacron, Plastics Machinery Division, Batavia, Ohio, USA.

When particles are made by direct compression, the addition of lubricants may be helpful and sometimes important to promote powder flow and to prevent capping of the particle (breaking off of a portion of the sphere) when the pressure is relieved. Useful lubricants are magnesium stearate (in a concentration of from 0.25% to 3% by weight, preferably less than 1% by weight, in the powder mix), and hydrogenated vegetable oil (preferably hydrogenated and refined triglycerides of stearic and palmitic acids at about 1% to 5% by weight, most preferably about 2% by weight. Additional excipients may be added to enhance powder flowability and reduce adherence.

Different drugs have different biological half-lives, and the frequency of administration needed for effective use of any single drug depends on the half-life of that drug. When two or more drugs are co-administered in a single dose using dosage forms of the prior art, an unfavorable compromise is often required, resulting in an underdose of one drug or an overdose of the other. The multi-particle dosage form of this invention permits different drugs to be placed in different matrix particles, each particle individually formulated to provide the release rate and duration that are optimal for the particular drug carried by that particle. This can be done by varying the matrix composition, the particle size, the particle molecular weights, or any other characteristic that affects the release rate and duration. The number of particles carrying individual drugs can also be varied among the different drugs. For example, a capsule made from three particles may contain two particles carrying one drug and one particle carrying the other drug.

Examples of drug combinations for which the formulations of this invention are useful are norethindrone plus ethinyl estradiol, a combination useful for

fertility control, acetaminophen plus codeine (a potent analgesic combination), captopril plus hydrochlorthiazide (a useful cardiovascular combination), clarithromycin plus omeprazole (for the eradication of *H. pylori*), and prednisolone plus cyclosporine (used for organ transplantation). In these and other examples, each ingredient can be
5 individually formulated to achieve a release rate that is optimal for the pharmacokinetics and biological activity of each drug. This invention is also useful as a means of co-administering drugs that cannot otherwise be combined in a single dosage form due to their chemical incompatibility.

The following examples are offered for purposes of illustration, and are
10 not intended to limit or to define the invention in any manner. All percents are by weight unless otherwise indicated.

EXAMPLE 1

Four dogs, all male beagles ranging in age from 10 months to 21 months and weighing from 6 kg to 10 kg each, were housed individually and each was fed a 1:1
15 (weight ratio) wet:dry mixture of food weighing 300 g once daily at 3:00 p.m. Water was provided *ad libitum*. The dogs were fasted for 6-8 hours overnight, preceded by the removal of feces and any uneaten food.

Test formulations were administered in various regimens. In some of the tests, the dogs were given an immediate release (IR) regimen in the form of a single
20 gelatin capsule containing a test species in a selected amount. A simulated controlled release (SCR) regimen was used in other tests by administering a gelatin capsule containing a test species in a selected amount every half hour. A third regimen was a controlled release (CR) regimen, in which the test species was incorporated in a compressed tablet of POLYOX 303 and magnesium stearate. (The arginine controlled-
25 release dosage form, for example, contained 300 mg arginine, 62.5% POLYOX 303 and 0.5% magnesium stearate, for a total weight of 800 mg, compressed after dry blending into a tablet measuring 7.94 × 19.05 mm. A test in which the tablet was immersed in simulated gastric fluid indicated that 55% of the arginine was released from this tablet within six hours.) Fifteen minutes after the administration of the test formulations in all
30 cases (or after the beginning of the administration regimen), each dog ingested two swelling tablets (weighing 400 mg and 800 mg, respectively, and measuring 6.15 ×

16.26 mm and 7.94×19.05 mm, respectively), each such tablet containing 25% barium sulfate (a radiopaque compound). The barium tablets were visualized every thirty minutes by fluoroscopy until they left the stomach. The time of the last observation of the 800 mg tablet in the stomach was recorded as the retention time. The test group also included a negative control using a fasted dog with no test formulations administered, and a positive control using a dog that was fed a standard 50 g meal but no test formulations.

The test results in terms of the retention times in hours are shown in Table I, which lists the mean of the results observed among the four dogs as well as the range among the dogs for each test.

10

TABLE I

Fed Mode Inducing Agents
and Resulting Retention Times for 7.94×19.05 mm BaSO₄ Tablet

Test Agent	Dosage (mg)	Regimen ^(a)	Retention Time (h)	
			Mean	Range
None – fasted (Negative Control)	--	--	0.9 ± 0.6	0.5 - 1.7
None – fed (Positive Control)	--	--	4.1 ± 0.8	3 - 4.5
Glycine hemihydrochloride	800	IR	3.1 ± 2.0	1.5 - 6
Xylitol	600	IR	3.1 ± 1.5	1.5 - 5
Na docusate	200	IR	2.6 ± 1.4	1 - 4.5
β -Casomorphin	25	IR	2.6 ± 1.1	1.5 - 4
α -Lipoic acid	150	IR	2.8 ± 1.6	1.5 - 5
Loperamide	0.1	IR	2.5 ± 1.3	1.5 - 4
L-Arginine	300	CR ^(b)	3.6 ± 1.6	2.5 - 6
L-Arginine	400	IR	1.6 ± 0.2	1.5 - 2
Trp-Trp	20	SCR ^(c)	2.8 ± 0.3	2.5 - 3
Trp-Trp	200	IR	3.1 ± 3.9	0.5 - 9

Trp-Trp	200	IR	2.1 ± 1.8	1 - 4.75
---------	-----	----	-----------	----------

- 5
- (a) IR: immediate release; CR: controlled release; SCR: simulated controlled release.
 - (b) The amount of arginine released by this formulation over a six-hour period was estimated at approximately 150 mg.
 - (c) Simulated controlled release was achieved by administering 20 mg of the agent every thirty minutes.

EXAMPLE 2

Further tests were performed on a second group of dogs, consisting of five female beagles one year in age and weighing 5-7 kg each. The test protocols were the same as those in Example 1 except that the dogs were fasted for 24 hours before each test, and the test results are listed in Table II below, which lists the mean of the results observed among the five dogs as well as the range among the dogs for each test.

10

TABLE II

Fed Mode Inducing Agents
and Resulting Retention Times for 7.94 × 19.05 mm BaSO₄ Tablet

Test Agent	Dosage (mg)	Regimen	Retention Time (h)	
			Mean	Range
None – fasted (Negative Control)	--	--	1.0 ± 0.2	0.75 - 1.25
None – fed (Positive Control)	--	--	5.4 ± 0.9	4 - 6
Trp-Trp	5	SCR ^(a)	4.6 ± 1.5	2.25 - 5.75
Trp-Trp	10	SCR ^(b)	2.4 ± 1.8	0.25 - 4.75
Trp-Trp	40	SCR ^(c)	3.4 ± 1.9	1.25 - 5.25
Cetylpyridinium chloride	20	IR	4.5 ± 2.6	0.75 - 6.75
Cetylpyridinium chloride	50	IR	4.0 ± 1.3	1.75 - 4.75
Cetylpyridinium chloride	100	IR	3.2 ± 0.9	2.75 - 4.25
Gentian root (gentisic acid)	200	IR	2.6 ± 1.4	1.25 - 4.75

^(a) Simulated controlled release was achieved by administering 5 mg of the agent every thirty minutes.

^(b) Simulated controlled release was achieved by administering 10 mg of the agent every thirty minutes.

^(c) Simulated controlled release was achieved by administering 40 mg of the agent every thirty minutes.

EXAMPLE 3

Further tests were performed on the second group of dogs, consisting of five female beagles one year in age and weighing 5-7 kg each. The test protocols were the same as those in Example 2, except that the controls were replaced by a negative control consisting of AVICEL (microcrystalline cellulose, FMC Corporation, Philadelphia, Pennsylvania, USA), administered as a simulated controlled release at

10 mg every half hour. The test results are listed in Table III below, which lists the mean of the results observed among the five dogs as well as the range among the dogs for each test.

TABLE III

5

Fed Mode Inducing Agents
and Resulting Retention Times for 7.94×19.05 mm BaSO₄ Tablet

Test Agent	Dosage (mg)	Regimen	Retention Time (h)	
			Mean	Range
AVICEL (Negative Control)	10	SCR ^(a)	1.4 ± 0.6	0.75 - 1.75
Cetylpyridinium chloride	20	IR	4.45 ± 2.6	0.75 - 6.75
Cetylpyridinium chloride	5	IR	4.0 ± 2.8	0.25 - 6.25
Glycine hemihydrochloride	20	SCR ^(b)	3.3 ± 1.3	1.75 - 5.25
Glycine hemihydrochloride	50	SCR ^(c)	3.8 ± 2.6	0.75 - 5.75
Glycine hemihydrochloride	5	SCR ^(d)	4.0 ± 1.8	1.25 - 6.25
Trp-Trp	2	SCR ^(e)	4.2 ± 1.1	2.75 - 5.25
Trp-Trp	0.5	SCR ^(f)	4.6 ± 1.7	2.25 - 6.25
Aspartame	200	IR	3.8 ± 2.3	1.75 - 5.25
β -Casomorphin	10	IR	3.5 ± 2.1	1.25 - 5.75

(a) Simulated controlled release was achieved by administering 10 mg of the agent every thirty minutes.

(b) Simulated controlled release was achieved by administering 20 mg of the agent every thirty minutes.

(c) Simulated controlled release was achieved by administering 50 mg of the agent every thirty minutes.

(d) Simulated controlled release was achieved by administering 5 mg of the agent every thirty minutes.


10

- (e) Simulated controlled release was achieved by administering 2 mg of the agent every thirty minutes.
- (f) Simulated controlled release was achieved by administering 0.5 mg of the agent every thirty minutes.

5 The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the components, proportions, dosages, formulations, and other parameters of the compositions and methods disclosed herein can be modified further or substituted in various ways without departing from the spirit and scope of the invention.


WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising:
 a drug retained in a solid matrix in a manner causing release of said drug
 from said solid matrix when said solid matrix is in the stomach,
 said solid matrix when in the stomach being of a size large enough
 to promote retention of said solid matrix in the stomach during the
 fed mode, and
 a fed mode inducing agent selected from the group consisting of:
- (a) glycine, glycylglycine and salts thereof,
 - (b) C₄-C₈ sugar alcohols,
 - (c) alkali and alkaline earth metal docusates,
 - (d) β-casomorphins,
 - (e) dithioorganic acids of the formula



in which n is 3 to 13,


- (f) 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides of the
 formula




in which:

- R¹ is a member selected from the group consisting of H,
 lower alkyl, and halo,
- R² is a member selected from the group consisting of H and
 methyl,
- R³ is a member selected from the group consisting of —
 CH₂CH₂— and —CH(CH₃)CH₂—,
- R⁴ is lower alkyl, and

- 26 R^5 is lower alkyl,
 27 (g) arginine and arginine salts,
 28 (h) the dipeptide Trp-Trp and salts thereof,
 29 (i) alkyl pyridinium halides of the formula



- 30 in which n is 8 to 20 and X is halide,
 31 (j) dihydroxybenzoic acids,
 32 (k) stevioside,
 33 (l) alkyl esters of N-L- α -aspartyl L-phenylalanine,
 34 (m) aspartic acid and salts thereof, and
 35 (n) 3,4-dihydro-1,2,3-oxathiazin-4-ones of the formula
 36



- 37 in which R^1 and R^2 are independently selected from the
 38 group consisting of H and C_1 - C_{10} alkyl, and salts thereof
 39 in an amount that causes onset of the fed mode.
 40

1 2. A pharmaceutical composition in accordance with claim 1 in which
 2 said fed mode inducing agent is retained in said solid matrix with said drug, said solid
 3 matrix causing release of both said fed mode reducing agent and said drug in a sustained
 4 manner.

1 3. A pharmaceutical composition in accordance with claim 1 in which
 2 said fed mode inducing agent resides in a surface coating or layer on said solid matrix,
 3 said surface coating or layer permitting substantially immediate release of said fed mode
 4 reducing agent upon contact with gastric fluid while said solid matrix causes release of
 5 said drug in a sustained manner.

1 4. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is separate from said solid matrix, said solid matrix causing
3 release of drug in a sustained manner.

1 5. A pharmaceutical composition in accordance with claim 1 in which
2 the size of said solid matrix prior to ingestion is sufficiently large to promote retention of
3 said solid matrix in the stomach during the fed mode.

1 6. A pharmaceutical composition in accordance with claim 1 in which
2 said solid matrix swells or expands upon contact with gastric fluid to a size sufficiently
3 large to promote retention of said solid matrix in the stomach during the fed mode.

1 7. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a member selected from the group consisting of glycine,
3 glycylglycine, and salts thereof.

1 8. A pharmaceutical composition in accordance with claim 7 in which
2 the amount of said fed mode inducing agent is from about 1 mg to about 500 mg.

1 9. A pharmaceutical composition in accordance with claim 7 in which
2 the amount of said fed mode inducing agent is from about 5 mg to about 150 mg.

1 10. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a C₄-C₈ sugar alcohol.

1 11. A pharmaceutical composition in accordance with claim 10 in
2 which said C₄-C₈ sugar alcohol is xylitol.

1 12. A pharmaceutical composition in accordance with claim 10 in
2 which the amount of said C₄-C₈ sugar alcohol is from about 30 mg to about 1000 mg.

1 13. A pharmaceutical composition in accordance with claim 10 in
2 which the amount of said C₄-C₈ sugar alcohol is from about 100 mg to about 800 mg.

1 14. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a member selected from the group consisting of alkali
3 and alkaline earth metal docusates.

1 15. A pharmaceutical composition in accordance with claim 14 in
2 which said fed mode inducing agent is a member selected from the group consisting of
3 calcium docusate and sodium docusate.

1 16. A pharmaceutical composition in accordance with claim 14 in
2 which said fed mode inducing agent is sodium docusate.

1 17. A pharmaceutical composition in accordance with claim 14 in
2 which the amount of said fed mode inducing agent is from about 30 mg to about
3 1000 mg.

1 18. A pharmaceutical composition in accordance with claim 14 in
2 which the amount of said fed mode inducing agent is from about 50 mg to about 400 mg.


1 19. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a β -casomorphin.

1 20. A pharmaceutical composition in accordance with claim 19 in
2 which said β -casomorphin is bovine β -casomorphin.

1 21. A pharmaceutical composition in accordance with claim 19 in
2 which the amount of said β -casomorphin is from about 1 mg to about 300 mg.

1 22. A pharmaceutical composition in accordance with claim 19 in
2 which the amount of said β -casomorphin is from about 5 mg to about 150 mg.

1 23. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a dithioorganic acid of the formula




3
4 in which n is 3 to 13.

1 24. A pharmaceutical composition in accordance with claim 23 in
2 which said dithioorganic acid is α -lipoic acid.

1 25. A pharmaceutical composition in accordance with claim 23 in
2 which the amount of said dithioorganic acid is from about 30 mg to about 1000 mg.

1 26. A pharmaceutical composition in accordance with claim 23 in
2 which the amount of said dithioorganic acid is from about 40 mg to about 300 mg.

1 27. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramide
3 of the formula



4 in which:

- 6 R¹ is a member selected from the group consisting of H, lower alkyl, and
7 halo,
8 R² is a member selected from the group consisting of H and methyl,
9 R³ is a member selected from the group consisting of —CH₂CH₂— and
10 —CH(CH₃)CH₂—,
11 R⁴ is lower alkyl, and
12 R⁵ is lower alkyl.

1 28. A pharmaceutical composition in accordance with claim 27 in
2 which:

- 3 R¹ is a member selected from the group consisting of H, C₁-C₃ alkyl,
4 fluoro, and chloro,
5 R² is a member selected from the group consisting of H and methyl,
6 R³ is a member selected from the group consisting of —CH₂CH₂— and
7 —CH(CH₃)CH₂—,
8 R⁴ is C₁-C₃ alkyl, and
9 R⁵ is C₁-C₃ alkyl.

1 29. A pharmaceutical composition in accordance with claim 27 in
2 which R¹ is 4-chloro, R² is H, R³ is —CH₂CH₂—, R⁴ is CH₃, and R⁵ is CH₃.

1 30. A pharmaceutical composition in accordance with claim 27 in
2 which the amount of said 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramide is from
3 about 0.5 mg to about 300 mg.

1 31. A pharmaceutical composition in accordance with claim 27 in
2 which the amount of said 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramide is from
3 about 2 mg to about 15 mg.

1 32. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a member selected from the group consisting of arginine
3 and arginine salts.

1 33. A pharmaceutical composition in accordance with claim 32 in
2 which the amount of said fed mode inducing agent is from about 3 mg to about 300 mg.


1 34. A pharmaceutical composition in accordance with claim 32 in
2 which the amount of said fed mode inducing agent is from about 30 mg to about 150 mg.

1 35. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a member selected from the group consisting of the
3 dipeptide Trp-Trp and Trp-Trp salts.

1 36. A pharmaceutical composition in accordance with claim 35 in
2 which the amount of said Trp-Trp is from about 0.05 mg to about 300 mg.

1 37. A pharmaceutical composition in accordance with claim 35 in
2 which the amount of said Trp-Trp is from about 0.5 mg to about 10 mg.

1 38. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is an alkyl pyridinium halide of the formula



3
4 in which n is 10 to 20 and X is halide.

- 1 39. A pharmaceutical composition in accordance with claim 38 in
2 which n is 12 to 16 and X is chloride.
- 1 40. A pharmaceutical composition in accordance with claim 38 in
2 which said alkyl pyridinium halide is cetyl pyridinium chloride.
- 1 41. A pharmaceutical composition in accordance with claim 38 in
2 which the amount of said alkyl pyridinium halide is from about 0.1 mg to about 200 mg.
- 1 42. A pharmaceutical composition in accordance with claim 38 in
2 which the amount of said alkyl pyridinium halide is from about 0.5 mg to about 50 mg.
- 1 43. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is a dihydroxybenzoic acid.
- 1 44. A pharmaceutical composition in accordance with claim 43 in
2 which said dihydroxybenzoic acid is gentisic acid.
- 1 45. A pharmaceutical composition in accordance with claim 43 in
2 which the amount of said dihydroxybenzoic acid is from about 3 mg to about 300 mg.
- 1 46. A pharmaceutical composition in accordance with claim 43 in
2 which the amount of said dihydroxybenzoic acid is from about 10 mg to about 100 mg.
- 1 47. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is retained in said dosage form in such a manner that said
3 fed mode inducing agent is released substantially immediately into gastric fluid upon
4 contact of said dosage form with said gastric fluid while said drug is released into said
5 gastric fluid in a sustained manner by dissolution and diffusion of said drug out of said
6 solid matrix, by erosion or dissolution of said matrix, or by osmotic pressure within said
7 solid matrix.
- 1 48. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is retained in said dosage form in such a manner that both
3 said drug and said fed mode inducing agent are released into gastric fluid in a sustained
4 manner by dissolution and diffusion of said drug and said fed mode inducing agent out of

5 said solid matrix, by erosion or dissolution of said matrix, or by osmotic pressure within
6 said solid matrix.

1 49. A pharmaceutical composition in accordance with claim 1 in which
2 said solid matrix is a member selected from the group consisting of cellulose polymers
3 and polyethylene oxide.

1 50. A pharmaceutical composition in accordance with claim 49 in
2 which said solid matrix is a member selected from the group consisting of
3 hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
4 hydroxypropylmethylcellulose, carboxymethylcellulose, and polyethylene oxide.

1 51. A pharmaceutical composition in accordance with claim 50 in
2 which said solid matrix is a member selected from the group consisting of
3 hydroxyethylcellulose, hydroxypropylcellulose, and polyethylene oxide.

1 52. A pharmaceutical composition in accordance with claim 1 in which
2 said fed mode inducing agent is contained in a solid coating adhering to a surface of said
3 solid matrix.

1 53. A pharmaceutical composition in accordance with claim 52 in
2 which said solid coating is comprised of said fed mode inducing agent suspended in a
3 water-soluble matrix.


1 54. A pharmaceutical composition in accordance with claim 52 in
2 which said water-soluble matrix is a member selected from the group consisting of
3 cellulose, vinyls, glycols and carbohydrates.

1 55. A pharmaceutical composition in accordance with claim 52 in
2 which said water-soluble matrix is a member selected from the group consisting of
3 sodium carboxymethylcellulose, sodium starch glycolate, crospovidone, microcrystalline
4 cellulose, lactose, and substituted hydroxypropylcellulose.

1 56. A method for pharmacologically inducing the fed mode in a
2 subject, said method comprising administering to said subject a fed mode inducing agent
3 selected from the group consisting of:


4 (a) glycine, glycylglycine and salts thereof,

- (b) C₄-C₈ sugar alcohols,
 (c) alkali and alkaline earth metal docusates,
 (d) β-casomorphins,
 (e) dithioorganic acids of the formula



in which n is 3 to 13,

- (f) 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides of the formula



in which:

R¹ is a member selected from the group consisting of H,
 lower alkyl, and halo,


R² is a member selected from the group consisting of H and
 methyl,

R³ is a member selected from the group consisting of —
 CH₂CH₂— and —CH(CH₃)CH₂—,

R⁴ is lower alkyl, and

R⁵ is lower alkyl,


- (g) arginine and arginine salts,
 (h) the dipeptide Trp-Trp and salts thereof,
 (i) alkyl pyridinium halides of the formula



in which n is 10 to 20 and X is halide,

- (j) dihydroxybenzoic acids,

- 29 (k) stevioside,
 30 (l) alkyl esters of N-L- α -aspartyl L-phenylalanine,
 31 (m) aspartic acid and salts thereof, and
 32 (n) 3,4-dihydro-1,2,3-oxathiazin-4-ones of the formula



- 33
 34 in which R¹ and R² are independently selected from the group
 35 consisting of H and C₁-C₁₀ alkyl, and salts thereof,
 36 in an amount that causes onset of the fed mode.

1 57. A method in accordance with claim 56 in which said fed mode
 2 inducing agent is a member selected from the group consisting of glycine, glycylglycine,
 3 and salts thereof.

1 58. A method in accordance with claim 57 in which the amount of said
 2 fed mode inducing agent is from about 1 mg to about 500 mg.

1 59. A method in accordance with claim 57 in which the amount of said
 2 fed mode inducing agent is from about 5 mg to about 150 mg.

1 60. A method in accordance with claim 56 in which said fed mode
 2 inducing agent is a C₄-C₈ sugar alcohol.

1 61. A method in accordance with claim 60 in which said C₄-C₈ sugar
 2 alcohol is xylitol.

1 62. A method in accordance with claim 60 in which the amount of said
 2 C₄-C₈ sugar alcohol is from about 30 mg to about 1000 mg.

1 63. A method in accordance with claim 60 in which the amount of said
 2 C₄-C₈ sugar alcohol is from about 100 mg to about 800 mg.

1 64. A method in accordance with claim 56 in which said fed mode
 2 inducing agent is a member selected from the group consisting of alkali and alkaline earth
 3 metal docusates.

1 65. A method in accordance with claim 64 in which said fed mode
2 inducing agent is a member selected from the group consisting of calcium docusate and
3 sodium docusate.

1 66. A method in accordance with claim 64 in which said fed mode
2 inducing agent is sodium docusate.

1 67. A method in accordance with claim 64 in which the amount of said
2 fed mode inducing agent is from about 30 mg to about 1000 mg.

1 68. A method in accordance with claim 64 in which the amount of said
2 fed mode inducing agent is from about 60 mg to about 400 mg.


1 69. A method in accordance with claim 56 in which said fed mode
2 inducing agent is a β -casomorphin.

1 70. A method in accordance with claim 69 in which said
2 β-casomorphin is bovine β-casomorphin.

1 71. A method in accordance with claim 69 in which the amount of said
2 β -casomorphin is from about 1 mg to about 300 mg.

1 72. A method in accordance with claim 69 in which the amount of said
2 β -casomorphin is from about 5 mg to about 150 mg.

1 73. A method in accordance with claim 56 in which said fed mode
2 inducing agent is a dithioorganic acid of the formula




4 in which n is 3 to 13.

1 74. A method in accordance with claim 73 in which said dithioorganic
2 acid is α -lipoic acid.

1 75. A method in accordance with claim 73 in which the amount of said
2 dithioorganic acid is from about 30 mg to about 1000 mg.

1 76. A method in accordance with claim 73 in which the amount of said
2 dithioorganic acid is from about 40 mg to about 300 mg.

1 77. A method in accordance with claim 56 in which said fed mode
2 inducing agent is a 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramide of the formula



3
4 in which:

5 R^1 is a member selected from the group consisting of H, lower alkyl, and
6 halo,
7 R^2 is a member selected from the group consisting of H and methyl,
8 R^3 is a member selected from the group consisting of $-\text{CH}_2\text{CH}_2-$ and
9 $-\text{CH}(\text{CH}_3)\text{CH}_2-$,
10 R^4 is lower alkyl, and
11 R^5 is lower alkyl.

1 78. A method in accordance with claim 77 in which:
2 R^1 is a member selected from the group consisting of H, C_1 - C_3 alkyl,
3 fluoro, and chloro,
4 R^2 is a member selected from the group consisting of H and methyl,
5 R^3 is a member selected from the group consisting of $-\text{CH}_2\text{CH}_2-$ and
6 $-\text{CH}(\text{CH}_3)\text{CH}_2-$,
7 R^4 is C_1 - C_3 alkyl, and
8 R^5 is C_1 - C_3 alkyl.

1 79. A method in accordance with claim 77 in which R^1 is 4-chloro, R^2
2 is H, R^3 is $-\text{CH}_2\text{CH}_2-$, R^4 is CH_3 , and R^5 is CH_3 .

1 80. A method in accordance with claim 77 in which the amount of said
2 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramide is from about 0.5 mg to about
3 300 mg.

1 81. A method in accordance with claim 77 in which the amount of said
2 2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramide is from about 2 mg to about 15 mg.

1 82. A method in accordance with claim 56 in which said fed mode
2 inducing agent is a member selected from the group consisting of arginine and arginine
3 salts.

1 83. A method in accordance with claim 82 in which the amount of said
2 fed mode inducing agent is from about 3 mg to about 300 mg.


1 84. A method in accordance with claim 82 in which the amount of said
2 fed mode inducing agent is from about 30 mg to about 150 mg.

1 85. A method in accordance with claim 56 in which said fed mode
2 inducing agent is a member selected from the group consisting of the dipeptide Trp-Trp
3 and Trp-Trp salts.

1 86. An oral drug dosage form in accordance with claim 85 in which the
2 amount of said Trp-Trp is from about 0.05 mg to about 300 mg.

1 87. An oral drug dosage form in accordance with claim 85 in which the
2 amount of said Trp-Trp is from about 0.5 mg to about 10 mg.

1 88. A method in accordance with claim 56 in which said fed mode
2 inducing agent is an alkyl pyridinium halide of the formula



3
4 in which n is 10 to 20 and X is halide.

1 89. A method in accordance with claim 88 in which n is 12 to 16 and X
2 is chloride.

1 90. A method in accordance with claim 88 in which said alkyl
2 pyridinium halide is cetyl pyridinium chloride.

1 91. A method in accordance with claim 88 in which the amount of said
2 alkyl pyridinium halide is from about 0.1 mg to about 200 mg.

1 92. A method in accordance with claim 88 in which the amount of said
2 alkyl pyridinium halide is from about 0.5 mg to about 50 mg.

1 93. A method in accordance with claim 56 in which said fed mode
2 inducing agent is a dihydroxybenzoic acid.

1 94. A method in accordance with claim 93 in which said
2 dihydroxybenzoic acid is gentisic acid.

1 95. A method in accordance with claim 93 in which the amount of said
2 dihydroxybenzoic acid is from about 3 mg to about 300 mg.

1 96. A method in accordance with claim 93 in which the amount of said
2 dihydroxybenzoic acid is from about 10 mg to about 100 mg.

1 97. A pharmaceutical composition comprising:
2 a drug retained in a first solid matrix in a manner causing release of said
3 drug from first said solid matrix when said first solid matrix is in
4 the stomach, said solid first matrix when in the stomach being of a
5 size large enough to promote the retention of said first solid matrix
6 in the stomach during the fed mode, and
7 a pharmacological fed mode inducing agent active in inducing onset of the
8 fed mode, said fed mode inducing agent retained in a second solid
9 matrix configured to release said fed mode inducing agent into the
10 stomach in a sustained manner.

1 98. A pharmaceutical composition in accordance with claim 97 in
2 which said first solid matrix and said second solid matrix are a common single matrix.

1 99. A pharmaceutical composition in accordance with claim 97 in
2 which said fed mode inducing agent is sufficiently potent that onset of said fed mode
3 results from release of an amount of said fed mode inducing agent that is less than
4 500 mg.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30082

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/50 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 427 798 A (LUDWIG JENNIE SUE G ET AL) 27 June 1995 (1995-06-27)</p> <p>column 1, line 67 -column 2, line 12 column 2, line 40 -column 3, line 14 column 6, line 55 -column 7, line 16; example 1 claims 1-8</p> <p style="text-align: center;">--- -/--</p>	<p>1,2,5-9, 48-50, 97-99</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

15 April 2002

Date of mailing of the international search report

25. 04. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Muller, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 1 029 892 A (SUWELACK SKIN & HEALTH CARE AG) 23 August 2000 (2000-08-23) page 2, column 1, line 3 - line 10 page 3, column 4, line 19 -page 4, column 5, line 16 page 7, column 12, line 58 -column 13, line 21 page 8, column 14, line 34 -page 9, column 16, line 48 page 10, column 18, line 13 -column 19, line 4 claims 1-3,29,31,35-38,40-42	1,2,5-9, 48,97-99
X	EFENTAKIS M; AL-HMOUND H: "The influence of surfactants on drug release from a hydrophobic matrix" INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 70, no. 1-2, 1991, pages 153-158, XP001064514 page 154, column 1, line 35 -column 2, line 28 page 155, column 2; figure 2	1,2, 38-42
X	EP 0 715 846 A (RHONE POULENC RORER GMBH) 12 June 1996 (1996-06-12) page 7; example 5	1,2, 5-13,47, 48,97-99
X	US 5 213 794 A (FRITSCH CHRISTIAN ET AL) 25 May 1993 (1993-05-25) column 3, line 55 - line 61 column 6 -column 7; example 2	1,2,5,6, 10-13, 47,48, 97-99
X	US 4 871 546 A (FELTZ DENNIS R ET AL) 3 October 1989 (1989-10-03) column 1, line 14 - line 42 column 2 -column 3; example 1	1,3-6, 14-16, 47,48, 52-54, 97-99
X	GB 1 330 829 A (SMITH KLINE FRENCH LAB) 19 September 1973 (1973-09-19) page 2, column 1, line 22 - line 47 page 3, column 1, line 52 -page 4, column 1, line 12	1-8, 14-18, 47,97-99

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 5 043 328 A (WEITHMANN KLAUS U) 27 August 1991 (1991-08-27)</p> <p>column 13 -column 14; examples 24,36 column 1, line 34 - line 38 column 16 -column 17; example 74 claim 1</p>	<p>1,2,5,6, 23,24, 35-37</p>
X	<p>EP 0 571 217 A (MCNEIL PPC INC) 24 November 1993 (1993-11-24)</p> <p>page 9 -page 12; examples I,II figures 1-4 claims 1-10</p>	<p>1-6, 27-31, 47-55, 97-99</p>
X	<p>US 4 470 980 A (HIGUCHI TAKERU ET AL) 11 September 1984 (1984-09-11)</p> <p>column 5 -column 7; examples 1,4,13,22,30,42 column 9; example 54 column 10, line 15 - line 21 claim 11</p>	<p>1,2,5,6, 48,49, 97-99</p>
X	<p>STEPHENS J. AND CO: "Osmolyte and Tryptophan receptors controlling gastric emptying in the dog" AMERICAN JOURNAL OF PHYSIOLOGY, vol. 231, 1976, pages 848-853, XP001064412 cited in the application page 849, column 2, line 47 -page 850, column 1, line 4 page 850, column 2; figure 3 page 852, column 1, line 21 - line 30</p>	<p>56-59</p>
A	<p>US 5 328 697 A (RAMAN SIVA N ET AL) 12 July 1994 (1994-07-12)</p> <p>column 1, line 40 - line 63 column 3, line 19 -column 5, line 14 column 5 -column 6; example 3 column 7 -column 8; examples 7,8 claims 1-3</p>	<p>1-9, 32-34, 47-59, 82-84, 97-99</p>
A	<p>WO 99 25321 A (SMITHKLINE BEECHAM CORP ;VENKATESH GOPADI M (US)) 27 May 1999 (1999-05-27)</p> <p>page 10, line 30 -page 12, line 26; examples 5-7 claims 8,11,12</p>	<p>1,2,5,6, 32-34, 48,49, 97-99</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/30082

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 47285 A (DEPOMED INC ;SHELL JOHN W (US)) 18 December 1997 (1997-12-18) the whole document -----	1-99

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/30082

Box I Observation where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 56-96 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: partially claims 1-6,47-56,97-99,
entirely claims 7-9,32-34,57-59,82-84

- 1.1. Claims: partially claims 1-6,47-56,97-99,
entirely claims 7-9,57-59

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellaable polymer, and glycine, glycyglycine and salts thereof.

- 1.2. Claims: partially claims 1-6,47-56,97-99,
entirely claims 32-34,82-84

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellaable polymer, and arginine and arginine salts.

- 1.3. Claims: partially claims 1-6,47-56,97-99
A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellaable polymer, and aspartic acid and salts thereof.

2. Claims: partially claims 1-6,47-56,97-99,
entirely claims 10-13,60-63

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellaable polymer, and C4-C8 sugars alcohols.

3. Claims: partially claims 1-6,47-56,97-99,
entirely claims 14-18,64-68

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellaable polymer, and alkali and alkaline earth metal docusates.

4. Claims: partially claims 1-6,47-56,97-99,
entirely claims 19-22,69-72

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellable polymer, and beta-casomorphins.

5. Claims: partially claims 1-6,47-56,97-99,
entirely claims 23-26,73-76

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellable polymer, and dithioorganic acids of formula X as defined in the present application.

6. Claims: partially claims 1-6,47-56,97-99,
entirely claims 27-31,77-81

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellable polymer, and
2,2-diaryl-4-(4'-aryl-4'-hydroxypiperidino)butyramides of formula X as defined in the present application.

7. Claims: partially claims 1-6,47-56,97-99,
entirely claims 35-37,85-87

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellable polymer, and the dipeptide Trp-Trp and salts thereof.

8. Claims: partially claims 1-6,47-56,97-99,
entirely claims 38-42,88-92

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellable polymer, and alkyl pyridinium halides of formula X as defined in the present application.

9. Claims: partially claims 1-6,47-56,97-99,
entirely claims 43-46,93-96

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swellable polymer, and dihydroxybenzoic acids.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claims: partially claims 1-6,47-56,97-99

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swelling polymer, and stevioside.

11. Claims: partially claims 1-6,47-56,97-99

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swelling polymer, and alkyl esters of N-L-alpha-aspartyl L-phenylalanine.

12. Claims: partially claims 1-6,47-56,97-99

A single dosage form for oral administration that includes a solid-state drug in a solid matrix of a water-swelling polymer, and 3,4-dihydro-1,2,3-oxathiazin-4-ones of formula X as defined in the present application.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/30082

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5427798	A	27-06-1995	AT 161422 T	15-01-1998
			AU 677595 B2	01-05-1997
			AU 4725893 A	15-03-1994
			CA 2142320 A1	03-03-1994
			DE 69316015 D1	05-02-1998
			DE 69316015 T2	16-04-1998
			EP 0656775 A1	14-06-1995
			ES 2111168 T3	01-03-1998
			WO 9404138 A1	03-03-1994
			GR 3025794 T3	31-03-1998
			HK 1004323 A1	20-11-1998
			IL 106693 A	10-06-1997
			JP 8500110 T	09-01-1996
			LU 90656 A9	15-01-2001
			MX 9304967 A1	31-05-1994
			NZ 254947 A	26-04-1996
			SG 43911 A1	14-11-1997
			ZA 9305942 A	13-02-1995
EP 1029892	A	23-08-2000	EP 1029892 A1	23-08-2000
			AU 2802800 A	29-08-2000
			BR 0007472 A	16-10-2001
			CN 1340079 T	13-03-2002
			CZ 20012783 A3	13-03-2002
			WO 0047668 A1	17-08-2000
			NO 20013883 A	09-10-2001
EP 0715846	A	12-06-1996	DE 4444052 A1	13-06-1996
			AU 698749 B2	05-11-1998
			AU 3794795 A	20-06-1996
			CA 2164776 A1	11-06-1996
			EP 0715846 A1	12-06-1996
			JP 8208521 A	13-08-1996
			US 6024987 A	15-02-2000
			ZA 9510428 A	18-06-1996
US 5213794	A	25-05-1993	DE 4036757 A1	21-05-1992
			AT 127019 T	15-09-1995
			CA 2055536 A1	18-05-1992
			DE 59106367 D1	05-10-1995
			DK 486863 T3	27-12-1995
			EP 0486863 A1	27-05-1992
			ES 2077766 T3	01-12-1995
			GR 3017267 T3	30-11-1995
			JP 4290816 A	15-10-1992
US 4871546	A	03-10-1989	NONE	
GB 1330829	A	19-09-1973	AU 470023 B	04-03-1976
			AU 4230972 A	22-11-1973
			BE 783321 A1	10-11-1972
			CA 997677 A1	28-09-1976
			DE 2224390 A1	13-12-1973
			ES 402545 A1	01-04-1975
			FR 2138011 A5	29-12-1972
			IE 36335 B1	13-10-1976
			NL 7206328 A	21-11-1972
			ZA 7202664 A	31-01-1973

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/30082

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5043328	A	27-08-1991	DE 3615710 A1	26-11-1987
			AT 77549 T	15-07-1992
			AU 603574 B2	22-11-1990
			AU 7264187 A	12-11-1987
			CA 1302266 A1	02-06-1992
			DE 3779958 D1	30-07-1992
			DK 235687 A	10-11-1987
			EP 0244832 A2	11-11-1987
			ES 2051705 T3	01-07-1994
			GR 3005768 T3	07-06-1993
			HU 44433 A2	28-03-1988
			IE 60273 B	29-06-1994
			IL 82459 A	31-07-1994
			JP 62267222 A	19-11-1987
			KR 9508306 B1	27-07-1995
			PT 84841 A ,B	01-06-1987
			ZA 8703299 A	02-11-1987
EP 0571217	A	24-11-1993	BR 1100507 A3	02-04-2002
			CA 2096575 A1	22-11-1993
			DE 69315257 D1	02-01-1998
			DE 69315257 T2	14-05-1998
			EP 0571217 A2	24-11-1993
			ES 2112387 T3	01-04-1998
			GR 93100197 A ,B	31-01-1994
			US 5599577 A	04-02-1997
			US 5679376 A	21-10-1997
			US 5716641 A	10-02-1998
			US 5980944 A	09-11-1999
US 4470980	A	11-09-1984	AT 29837 T	15-10-1987
			CA 1165690 A1	17-04-1984
			DE 3176461 D1	29-10-1987
			DK 101981 A	08-09-1981
			EP 0036534 A1	30-09-1981
			ES 500184 D0	01-12-1982
			ES 8301107 A1	16-02-1983
			FI 810637 A	08-09-1981
			GR 74441 A1	28-06-1984
			IE 52973 B1	27-04-1988
			JP 1495937 C	16-05-1989
			JP 56128714 A	08-10-1981
			JP 63046727 B	19-09-1988
			MX 6955 E	29-12-1986
			NO 810758 A ,B,	08-09-1981
			PT 72616 A ,B	01-04-1981
US 5328697	A	12-07-1994	AT 145552 T	15-12-1996
			AU 3661093 A	03-09-1993
			CA 2129754 A1	11-08-1993
			CN 1075253 A ,B	18-08-1993
			DE 69306243 D1	09-01-1997
			DE 69306243 T2	20-03-1997
			DK 625900 T3	02-06-1997
			EP 0625900 A1	30-11-1994
			ES 2095045 T3	01-02-1997
			JP 8502020 T	05-03-1996
			NZ 249658 A	28-05-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/30082

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5328697	A	WO 9315725 A1	19-08-1993
WO 9925321	A	27-05-1999	
		AU 1588799 A	07-06-1999
		BR 9814877 A	03-10-2000
		CA 2310028 A1	27-05-1999
		CN 1285739 T	28-02-2001
		EP 1033974 A1	13-09-2000
		JP 2001522872 T	20-11-2001
		NO 20002526 A	16-05-2000
		PL 340587 A1	12-02-2001
		TR 200001412 T2	21-09-2000
		WO 9925321 A1	27-05-1999
WO 9747285	A	18-12-1997	
		AU 3290397 A	07-01-1998
		WO 9747285 A1	18-12-1997